Table 2. Estimated OR and 95% CI produced by random effects pairwise meta-analysis for adverse events in advanced/metastatic non-small-cell lung cancer (NSCLC) patients.
| Included studies | Comparisons | Adverse events | Pairwise meta-analysis | |||
|---|---|---|---|---|---|---|
| Treatment1 | Treatment2 | OR (95% CI) | I2 | Ph | ||
| Adverse events (all grades) | ||||||
| Diarrhea | ||||||
| 2 studies | A vs. B | 257/600 | 220/604 | 1.31 (1.04∼1.65) | 0.00% | 0.981 |
| 2 studies | A vs. E | 189/541 | 368/537 | 0.28 (0.16∼0.46) | 53.00% | 0.145 |
| Fatigue or Asthenia | ||||||
| 2 studies | A vs. B | 228/600 | 254/604 | 0.87 (0.63∼1.21) | 23.50% | 0.253 |
| 2 studies | A vs. E | 103/541 | 140/537 | 0.67 (0.50∼0.89) | 0.00% | 0.794 |
| Nausea or Vomiting | ||||||
| 2 studies | A vs. B | 239/600 | 238/604 | 0.92 (0.58∼1.47) | 55.00% | 0.136 |
| 2 studies | A vs. E | 120/541 | 191/537 | 0.52 (0.39∼0.68) | 0.00% | 0.604 |
| Decreased appetite | ||||||
| 2 studies | A vs. E | 86/541 | 156/537 | 0.46 (0.34∼0.62) | 0.00% | 0.48 |
| Dyspnoea | ||||||
| 2 studies | A vs. B | 139/600 | 154/604 | 0.87 (0.67∼1.14) | 6.40% | 0.301 |
Notes: OR = odds ratio; 95% CI = 95% confidence interval; NA = not available; A = Erlotinib + Placebo; B = Erlotinib + Tivantinib; E = Erlotinib + Sunitinib.